FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955264956> ?p ?o ?g. }

• W2955264956 endingPage "4687" @default.
• W2955264956 startingPage "4678" @default.
• W2955264956 abstract "Abstract Background E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculations of either E39 or E39′ (an attenuated version of E39) to prevent recurrences in disease‐free endometrial and ovarian cancer patients(pts). Here, we present the final 24‐month landmark analysis. Patients and methods HLA‐A2 + patients receiving E39 + GM‐CSF were included in the vaccine group (VG), and HLA‐A2‐ pts (or HLA‐A2 + patients refusing vaccine) were followed as the control group (CG). VG group received 6 monthly inoculations as the primary vaccine series (PVS) and were randomized to receive either E39 or E39′ booster inoculations. Demographic, safety, immunologic, and disease‐free survival (DFS) data were collected and evaluated. Results Fifty‐one patients were enrolled; 29 in the VG and 22 in the CG. Fourteen patients received <1000 μg and 15 received 1000 μg of E39. There were no clinicopathologic differences between VG and CG or between dose groups. E39 was well tolerated. At the 24 months landmark, DFS was 55.5% (VG) vs 40.0% (CG), P = 0.339. Patients receiving 1000 μg and boosted patients also showed improved DFS ( P < 0.03). DFS was improved in the 1000 μg group after treatment of primary disease (90.0% vs CG:42.9%, P = 0.007), but not in recurrent patients. In low‐FBP expressing patients, DFS was 100.0% (1000 μg), 50.0% (<1000 μg), and 25.0% (CG), P = 0.029. Conclusions This phase I/IIa trial reveals that E39 + GM‐CSF is safe and may be effective in preventing recurrence in high‐risk ovarian and endometrial cancer when optimally dosed (1000 μg) to FBP low patients being treated for primary disease." @default.
• W2955264956 created "2019-07-12" @default.
• W2955264956 creator A5021492589 @default.
• W2955264956 creator A5021690080 @default.
• W2955264956 creator A5034838741 @default.
• W2955264956 creator A5035547335 @default.
• W2955264956 creator A5042613508 @default.
• W2955264956 creator A5044161354 @default.
• W2955264956 creator A5044899007 @default.
• W2955264956 creator A5050537038 @default.
• W2955264956 creator A5061745540 @default.
• W2955264956 creator A5065391640 @default.
• W2955264956 creator A5074845988 @default.
• W2955264956 creator A5075148164 @default.
• W2955264956 creator A5080595928 @default.
• W2955264956 creator A5081216998 @default.
• W2955264956 creator A5083639898 @default.
• W2955264956 creator A5085457452 @default.
• W2955264956 creator A5089299085 @default.
• W2955264956 date "2019-07-05" @default.
• W2955264956 modified "2023-10-01" @default.
• W2955264956 title "Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients" @default.
• W2955264956 cites W1699177402 @default.
• W2955264956 cites W1976002760 @default.
• W2955264956 cites W1984997943 @default.
• W2955264956 cites W1993231275 @default.
• W2955264956 cites W2014910913 @default.
• W2955264956 cites W2082851035 @default.
• W2955264956 cites W2087162329 @default.
• W2955264956 cites W2112506009 @default.
• W2955264956 cites W2155240407 @default.
• W2955264956 cites W2167898988 @default.
• W2955264956 cites W2180645599 @default.
• W2955264956 cites W2307372011 @default.
• W2955264956 cites W2555631417 @default.
• W2955264956 cites W2619908690 @default.
• W2955264956 cites W2745792339 @default.
• W2955264956 cites W2793778387 @default.
• W2955264956 cites W4252291079 @default.
• W2955264956 doi "https://doi.org/10.1002/cam4.2378" @default.
• W2955264956 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6712444" @default.
• W2955264956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31274231" @default.
• W2955264956 hasPublicationYear "2019" @default.
• W2955264956 type Work @default.
• W2955264956 sameAs 2955264956 @default.
• W2955264956 citedByCount "22" @default.
• W2955264956 countsByYear W29552649562020 @default.
• W2955264956 countsByYear W29552649562021 @default.
• W2955264956 countsByYear W29552649562022 @default.
• W2955264956 countsByYear W29552649562023 @default.
• W2955264956 crossrefType "journal-article" @default.
• W2955264956 hasAuthorship W2955264956A5021492589 @default.
• W2955264956 hasAuthorship W2955264956A5021690080 @default.
• W2955264956 hasAuthorship W2955264956A5034838741 @default.
• W2955264956 hasAuthorship W2955264956A5035547335 @default.
• W2955264956 hasAuthorship W2955264956A5042613508 @default.
• W2955264956 hasAuthorship W2955264956A5044161354 @default.
• W2955264956 hasAuthorship W2955264956A5044899007 @default.
• W2955264956 hasAuthorship W2955264956A5050537038 @default.
• W2955264956 hasAuthorship W2955264956A5061745540 @default.
• W2955264956 hasAuthorship W2955264956A5065391640 @default.
• W2955264956 hasAuthorship W2955264956A5074845988 @default.
• W2955264956 hasAuthorship W2955264956A5075148164 @default.
• W2955264956 hasAuthorship W2955264956A5080595928 @default.
• W2955264956 hasAuthorship W2955264956A5081216998 @default.
• W2955264956 hasAuthorship W2955264956A5083639898 @default.
• W2955264956 hasAuthorship W2955264956A5085457452 @default.
• W2955264956 hasAuthorship W2955264956A5089299085 @default.
• W2955264956 hasBestOaLocation W29552649561 @default.
• W2955264956 hasConcept C121608353 @default.
• W2955264956 hasConcept C126322002 @default.
• W2955264956 hasConcept C143998085 @default.
• W2955264956 hasConcept C147483822 @default.
• W2955264956 hasConcept C195616568 @default.
• W2955264956 hasConcept C203014093 @default.
• W2955264956 hasConcept C2776789287 @default.
• W2955264956 hasConcept C2780427987 @default.
• W2955264956 hasConcept C71924100 @default.
• W2955264956 hasConcept C90924648 @default.
• W2955264956 hasConceptScore W2955264956C121608353 @default.
• W2955264956 hasConceptScore W2955264956C126322002 @default.
• W2955264956 hasConceptScore W2955264956C143998085 @default.
• W2955264956 hasConceptScore W2955264956C147483822 @default.
• W2955264956 hasConceptScore W2955264956C195616568 @default.
• W2955264956 hasConceptScore W2955264956C203014093 @default.
• W2955264956 hasConceptScore W2955264956C2776789287 @default.
• W2955264956 hasConceptScore W2955264956C2780427987 @default.
• W2955264956 hasConceptScore W2955264956C71924100 @default.
• W2955264956 hasConceptScore W2955264956C90924648 @default.
• W2955264956 hasIssue "10" @default.
• W2955264956 hasLocation W29552649561 @default.
• W2955264956 hasLocation W29552649562 @default.
• W2955264956 hasLocation W29552649563 @default.
• W2955264956 hasOpenAccess W2955264956 @default.
• W2955264956 hasPrimaryLocation W29552649561 @default.
• W2955264956 hasRelatedWork W1978923481 @default.
• W2955264956 hasRelatedWork W2004664608 @default.
• W2955264956 hasRelatedWork W2014119546 @default.

• next